Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association最新文献_第8页

Plasma Glucose Concentrations in Different Sampling Tubes Measured on Different Glucose Analysers. 用不同的葡萄糖分析仪测量不同采样管中的血浆葡萄糖浓度。

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-05-01 Epub Date: 2024-02-02 DOI: 10.1055/a-2260-3715

Stefan Pleus, Alexandra Beil, Annette Baumstark, Cornelia Haug, Guido Freckmann

{"title":"Plasma Glucose Concentrations in Different Sampling Tubes Measured on Different Glucose Analysers.","authors":"Stefan Pleus, Alexandra Beil, Annette Baumstark, Cornelia Haug, Guido Freckmann","doi":"10.1055/a-2260-3715","DOIUrl":"10.1055/a-2260-3715","url":null,"abstract":"Introduction: The German Diabetes Association recommends using sampling tubes with citrate and fluoride additives to diagnose diabetes by oral glucose tolerance test to inhibit glycolysis. The effect of different tubes on measurement results was assessed.Materials and methods: In a first study, an oral glucose tolerance test was performed on 41 participants without anamnestically known diabetes. Venous blood was sampled in two different tubes with citrate/fluoride additives from different manufacturers and one with only lithium-heparin additive. A second study with 42 participants was performed to verify the initial results with an adapted design, in which a third tube with citrate buffer was used, and glucose measurements were performed on two additional devices of another analyser model. Samples were centrifuged either immediately (<5 min incubation time) or after 20 min or 4 h. All glucose measurements were performed in plasma. Glucose concentrations in lithium-heparin tubes with<5 min incubation time served as baseline concentrations.Results: In the first study, glucose concentrations in one of the citrate/fluoride tubes were similar to the baseline. In the other citrate/fluoride tube, markedly lower concentrations (approximately - 5 mg/dL (- 0.28 mmol/L)) were measured. This was reproduced in the verification study for the same analyser, but not with the other analyser model. Lithium-heparin tubes centrifuged after 20 and 240 min showed systematically lower glucose concentrations.Conclusions: The results confirm that glycolysis can be effectively inhibited in citrate/fluoride-containing sampling tubes. However, glucose measurement results of one analyser showed a relevant negative bias in tubes containing liquid citrate buffer.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":" ","pages":"260-266"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139673912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Analysis of Dietary Inflammatory Index and Gestational Diabetes Mellitus: Based on National Health and Nutrition Examination Survey Database. 膳食炎症指数与妊娠糖尿病的关联分析：基于全国健康与营养调查数据库

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-04-25 DOI: 10.1055/a-2293-7983

Yamin Zeng, Yina Piao

{"title":"Association Analysis of Dietary Inflammatory Index and Gestational Diabetes Mellitus: Based on National Health and Nutrition Examination Survey Database.","authors":"Yamin Zeng, Yina Piao","doi":"10.1055/a-2293-7983","DOIUrl":"https://doi.org/10.1055/a-2293-7983","url":null,"abstract":"OBJECTIVE\u0000This study focused on the association of the Dietary Inflammatory Index (DII) with the risk of gestational diabetes mellitus (GDM) using data from the National Health and Nutrition Examination Survey (NHANES).\u0000\u0000\u0000METHODS\u0000Data from two cycles of NHANES (2007-2010) were analyzed. Weighted logistic regression models were constructed to explore the relationship between DII and GDM. Stratified and subgroup analyses with adjustment for confounding factors were carried out to explore the association between DII and GDM. Mediation analysis was conducted to investigate potential mediating factors.\u0000\u0000\u0000RESULTS\u0000A total of 1,421 samples were analyzed. Based on the weighted logistic regression model, a strong positive association was observed between DII score and GDM risk (OR: 1.14, 95%CI: 1.02-1.26, P<0.01), suggesting that a pro-inflammatory diet could considerably increase the likelihood of GDM occurrence. This positive association was particularly significant in populations who consume alcohol (OR:1.17, 95%CI: 1.03-1.34, P<0.01) and have a body mass index>30 kg/m² (OR: 1.18, 95% CI: 1.01-1.38, P<0.05). Mediation analysis indicated that the white blood cell count mediated the association between DII and GDM, with an indirect effect of 0.000828 (95% CI: 0.000226-0.001347, P=0.001) and a mediation proportion of 8.01%. Specifically, the neutrophil count as a component contributed to this mediation effect (0.000774, 95% CI: 0.00014-0.001063, P=0.001), with a mediation proportion of 7.59%.\u0000\u0000\u0000CONCLUSION\u0000A pro-inflammatory diet in women elevates the likelihood of GDM occurrence. An anti-inflammatory dietary pattern may be a protective intervention for GDM.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"1 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140653903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapy combining glucagon-like peptide-1 receptor agonist with sodium-glucose cotransporter 2 inhibitor suppresses atherosclerosis in diabetic ApoE-deficient mice. 胰高血糖素样肽-1 受体激动剂与钠-葡萄糖共转运体 2 抑制剂相结合的疗法可抑制糖尿病载脂蛋白E缺陷小鼠的动脉粥样硬化。

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-04-16 DOI: 10.1055/a-2307-8036

Masahiro Takubo, Kentaro Watanabe, Hitoki Saito, Genta Kohno, Hisamitsu Ishihara

{"title":"Therapy combining glucagon-like peptide-1 receptor agonist with sodium-glucose cotransporter 2 inhibitor suppresses atherosclerosis in diabetic ApoE-deficient mice.","authors":"Masahiro Takubo, Kentaro Watanabe, Hitoki Saito, Genta Kohno, Hisamitsu Ishihara","doi":"10.1055/a-2307-8036","DOIUrl":"https://doi.org/10.1055/a-2307-8036","url":null,"abstract":"Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) have beneficial effects on cardiovascular disease in addition to their glucose-lowering effects. We directly compared the effects of these drugs when used individually or in combination on cardiovascular atherosclerotic lesion development using diabetic ApoE-deficient hyperlipidemic mice. Methods We treated ApoE-deficient mice with streptozotocin and nicotinamide, generating a type 2 diabetes model. The mice were randomly divided into four groups: vehicle-treated (Untreated), liraglutide (LIRA), ipragliflozin (IPRA), and combination therapy (Combo). These mice as well as non-diabetic controls were fed a high-fat diet. After 8 weeks of drug administration, the heart and aorta were removed and analyzed. Results Atherosclerotic lesions evaluated by oil red O (ORO) staining were significantly larger in the Untreated group (13.4 ± 0.8% of total aortic area) than in the non-diabetic controls (4.4 ± 0.5%, p < 0.01), while being reduced in the Combo (6.0 ± 1.0%, p < 0.01) as compared with the Untreated group. The ORO stain-positive area in the LIRA and IPRA groups tended to be reduced but their differences failed to reach statistical significance. Transcript levels of Mcp1 and Sirt1 were significantly reduced and increased, respectively, in the Combo as compared with the Untreated group, while no significant changes were observed in the monotherapy groups. Conclusions Our data suggest that combination therapy with liraglutide and ipragliflozin may be an efficient regimen for preventing the development of atherosclerosis in diabetic ApoE-deficient mice.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"74 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140695427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and incidence of medication-treated diabetes and pattern of glucose-lowering treatment during the COVID-19 pandemic: real-world data from the electronic Greek prescription database. COVID-19 大流行期间药物治疗糖尿病的流行率和发病率以及降糖治疗模式：来自希腊电子处方数据库的真实世界数据。

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-04-16 DOI: 10.1055/a-2307-4631

C. Siafarikas, Georgios Karamanakos, K. Makrilakis, Anastasios Tsolakidis, Konstantinos Mathioudakis, Stavros Liatis

{"title":"Prevalence and incidence of medication-treated diabetes and pattern of glucose-lowering treatment during the COVID-19 pandemic: real-world data from the electronic Greek prescription database.","authors":"C. Siafarikas, Georgios Karamanakos, K. Makrilakis, Anastasios Tsolakidis, Konstantinos Mathioudakis, Stavros Liatis","doi":"10.1055/a-2307-4631","DOIUrl":"https://doi.org/10.1055/a-2307-4631","url":null,"abstract":"OBJECTIVES\u0000The aim of this study was to investigate the prevalence and incidence of medication-treated diabetes mellitus and the evolving patterns of glucose-lowering treatments, the year before and, during the first two years of the COVID-19 pandemic.\u0000\u0000\u0000METHODS\u0000Data from the Greek electronic prescription database were analyzed for the years 2019, 2020, and 2021. The study population included individuals with active social security numbers. Prevalence and incidence rates were calculated based on the dispensing of glucose-lowering medications, according to their unique ATC (anatomical therapeutic chemical) code.\u0000\u0000\u0000RESULTS\u0000The study population comprised 10,289,140 individuals in 2019, 10,630,726 in 2020, and 11,246,136 in 2021. Diabetes prevalence rates were 8.06%, 6.89%, and 7.91%, and incidence rates were 16.8/1000, 8.6/1000, and 13.4/1000 individuals, respectively. Metformin was the most prescribed medication, and newer classes, like SGLT-2 inhibitors and GLP-1 receptor agonists exhibited increasing trends.\u0000\u0000\u0000CONCLUSIONS\u0000The study identified a decrease in medication-prescribed diabetes prevalence and incidence during the initial year of the COVID-19 pandemic, attributed to healthcare access restrictions. Subsequently, figures returned close to baseline levels. Glucose-lowering medication trends reflected adherence to local and international guidelines, with metformin as the cornerstone, and increasing preference for newer classes such as GLP-1 receptor agonists and SGLT-2 inhibitors.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"15 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140696631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents. 儿童和青少年糖尿病的诊断、治疗和随访。

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-04-11 DOI: 10.1055/a-2166-6730

Martin Holder, Thomas Kapellen, Ralph Ziegler, J. Bürger-Büsing, Thomas Danne, Axel Dost, Reinhard W. Holl, P.-M. Holterhus, B. Karges, Olga Kordonouri, Karin Lange, Susanne Müller, K. Raile, Roland Schweizer, Simone von Sengbusch, Rainer Stachow, Verena Wagner, Susanna Wiegand, Andreas Neu

{"title":"Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents.","authors":"Martin Holder, Thomas Kapellen, Ralph Ziegler, J. Bürger-Büsing, Thomas Danne, Axel Dost, Reinhard W. Holl, P.-M. Holterhus, B. Karges, Olga Kordonouri, Karin Lange, Susanne Müller, K. Raile, Roland Schweizer, Simone von Sengbusch, Rainer Stachow, Verena Wagner, Susanna Wiegand, Andreas Neu","doi":"10.1055/a-2166-6730","DOIUrl":"https://doi.org/10.1055/a-2166-6730","url":null,"abstract":"Affiliations 1 Clinic for Paediatrics and Youth Medicine, University Hospital, Tübingen, Germany 2 Association of Diabetic Children and Adolescents, Diabetes Center, Kaiserslautern, Germany 3 Paediatric and Juvenile Hospital, Hanover, Germany 4 Clinic for Paediatrics and Juvenile Medicine, University Hospital Jena, Germany 5 Olga Hospital, Clinic Stuttgart, Germany 6 Institute for Epidemiology and Medical Biometry, ZIBMT, University of Ulm, Germany 7 Clinic for General Paediatrics, University Hospital Schleswig-Holstein, Kiel Campus, Germany 8 Clinic and Policlinic for Paediatrics and Juvenile Medicine, University Hospital, Leipzig, Germany 9 Endocrinology and Diabetology Section, University Hospital, RWTH Aachen University, Germany 10 Medical Psychology, Hannover Medical School, Hannover, Germany 11 Practice for Nutrition Consultation, Ennepetal, Germany 12 Virchow-Clinic, University Medicine, Berlin, Germany 13 Clinic for Paediatrics and Juvenile Medicine, University Hospital Schleswig-Holstein, Campus Lübeck, Germany 14 Sylt Specialist Clinic for Children and Adolescents, Westerland, Germany 15 Joint Practice for Paediatrics and Juvenile Medicine, Rostock, Germany 16 Practice for Paediatrics and Juvenile Medicine, Focus on Diabetology, Münster, Germany Bibliography DOI https://doi.org/10.1055/a-1018-8963 Exp Clin Endocrinol Diabetes 2019; 127 (Suppl 1): S39–S72 © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York ISSN 0947-7349","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"33 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140716618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of once-weekly subcutaneous semaglutide in adults with overweight or obesity: systematic review with meta-analysis. 每周一次皮下注射塞马鲁肽治疗成人超重或肥胖症的疗效和安全性：系统综述与荟萃分析。

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-04-10 DOI: 10.1055/a-2303-8558

G. Dorneles, Ellen Algeri, Gerhard Lauterbach, Marcelo Pereira, Brigida Fernandes

{"title":"Efficacy and safety of once-weekly subcutaneous semaglutide in adults with overweight or obesity: systematic review with meta-analysis.","authors":"G. Dorneles, Ellen Algeri, Gerhard Lauterbach, Marcelo Pereira, Brigida Fernandes","doi":"10.1055/a-2303-8558","DOIUrl":"https://doi.org/10.1055/a-2303-8558","url":null,"abstract":"BACKGROUND\u0000To evaluate the efficacy and safety of once-weekly subcutaneous semaglutide treatment in overweight or obese patients without type 2 diabetes.\u0000\u0000\u0000METHODS\u0000Randomized clinical trials that accessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from Pubmed, EMBASE, and Lilacs up to November 2023. Risk of bias was assessed with RoB 2.0, and certainty of evidence (CoE) with GRADE. We conducted a random-effects meta-analysis.\u0000\u0000\u0000RESULTS\u0000We included ten publications with 22.155 patients. Semaglutide decreased relative body weight (MD: -11.80; 95%CI: -13.53 to -10.07; CoE: High), absolute body weight (MD: -11.58; 95%CI: -13.25 to -9.90; CoE: High) and BMI (MD: -4.15; 95%CI: -4.85 to -3.45; CoE: High). Semaglutide also increased the proportion of patients who achieved 5%, 10% and 15% of weight loss ([weight loss ≥5%: RR 2.29, 95% CI: 1.88 to 2.80; CoE: High]; [weight loss ≥10%: RR 4.54, 95% CI: 3.45 to 5.98; CoE: High]; [weight loss ≥15%: RR 8.29, 95%CI: 5.54 to 12.39; CoE: High]). Semaglutide leads to small risk to adverse events (RR: 1.03; 95%CI: 1 to 1.06; CoE: High), no difference in the serious adverse events (RR: 1.07; 95%CI: 0.70 - 1.62; CoE: Low), but increases in the risk to discontinued treatment (RR: 2.03; 95%CI: 1.87 - 2.20; CoE: High) and gastrointestinal adverse events (RR: 3.26; 95%CI: 1.99 - 5.34; CoE: Moderate).\u0000\u0000\u0000CONCLUSION\u0000This up-to-date systematic review highlights that once-weekly semaglutide treatment resulted in clinically important weight loss, becoming a promising adjuvant therapy to treat obesity.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140717328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapy of Type 2 Diabetes. 治疗 2 型糖尿病。

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-04-10 DOI: 10.1055/a-2166-6755

Rüdiger Landgraf, J. Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel

引用次数: 0

Protective role of MerTK in diabetic peripheral neuropathy via inhibition of the NF-κb signaling pathway. MerTK 通过抑制 NF-κb 信号通路在糖尿病周围神经病变中的保护作用

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-04-08 DOI: 10.1055/a-2301-3970

Xiaoyang Su, Wenting Chen, Yidan Fu, Bian Wu, Fugang Mao, Yan Zhao, Qiuping Yang, Danfeng Lan

{"title":"Protective role of MerTK in diabetic peripheral neuropathy via inhibition of the NF-κb signaling pathway.","authors":"Xiaoyang Su, Wenting Chen, Yidan Fu, Bian Wu, Fugang Mao, Yan Zhao, Qiuping Yang, Danfeng Lan","doi":"10.1055/a-2301-3970","DOIUrl":"https://doi.org/10.1055/a-2301-3970","url":null,"abstract":"Diabetic peripheral neuropathy impacts patient quality of life. Increased Mer tyrosine kinase expression has been demonstrated in such patients, yet its mechanism remains unclear. This study established type 2 diabetes mellitus and diabetic peripheral neuropathy models in Sprague Dawley rats via low-dose streptozotocin and a high-fat diet. Mer tyrosine kinase-specific inhibitors were administered by gavage once daily for 2 weeks. Sciatic nerve conduction velocity and nerve structure were measured. The levels of Mer tyrosine kinase, nuclear factor kappa-light-chain-enhancer of activated B cells, tumor necrosis factor-alpha, interleukin-1 beta, and relevant biochemical indexes were detected. The study revealed Mer tyrosine kinase upregulation in type 2 diabetes mellitus and more so in diabetic peripheral neuropathy groups. Inhibiting Mer tyrosine kinase led to reduced nerve conduction velocity and further deterioration of sciatic nerve structure, as evidenced by structural morphology. Concurrently, serum levels of total cholesterol, glycated hemoglobin, and triglyceride significantly rose. Moreover, nuclear factor kappa-light-chain-enhancer of activated B cells levels increased in both serum and nerve tissue, alongside a significant rise in tumor necrosis factor-alpha and interleukin-1 beta expressions. Mer tyrosine kinase was found to bind to inhibitor of kappa B kinase beta in Schwann cells, establishing inhibitor of kappa B kinase beta as a precursor to nuclear factor kappa-light-chain-enhancer of activated B cells activation. Inhibition of Mer tyrosine kinase exacerbates neuropathy, indicating its protective role in diabetic peripheral neuropathy by suppressing the nuclear factor kappa-light-chain-enhancer of activated B cells pathway, highlighting a potential new target for its diagnosis and treatment.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"188 1‐6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140730901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subtyping of Cushing's syndrome: a step ahead. 库欣综合征的亚型划分：向前迈进了一步。

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-04-04 DOI: 10.1055/a-2299-5065

I. Tizianel, M. Barbot, F. Ceccato

引用次数: 0

Beneficial effects of Echinacoside on cognitive impairment and diabetes in type 2 diabetic db/db mice. 紫锥栗苷对 2 型糖尿病 db/db 小鼠认知障碍和糖尿病的有益影响

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association Pub Date : 2024-04-03 DOI: 10.1055/a-2298-4593

Fanglin Qin, Yiming Yan, Ningxi Yang, Yarong Hao

{"title":"Beneficial effects of Echinacoside on cognitive impairment and diabetes in type 2 diabetic db/db mice.","authors":"Fanglin Qin, Yiming Yan, Ningxi Yang, Yarong Hao","doi":"10.1055/a-2298-4593","DOIUrl":"https://doi.org/10.1055/a-2298-4593","url":null,"abstract":"Cognitive dysfunction is an important comorbidity of diabetes. Insulin resistance may play a critical role in diabetes-related cognitive impairment. Echinacoside(ECH), a natural phenylethanoid glycoside, is the active component of anti-diabetes prescriptions in traditional Chinese medicine. Its effect on modulating insulin resistance has been confirmed but modulating neurodegenerative disease still remains to be clarified. Db/db mice, a spontaneous Type 2 diabetes （T2D）mode, were intragastrically administered various doses of ECH or an equivalent volume of saline. Weight, blood glucose, and insulin resistance index were measured. Morris water maze was used to observe the compound effects on cognition. Hippocampal lesions were observed by histochemical analysis. In db/db mice, ECH alleviates diabetes symptoms, memory loss, and hippocampal neuronal damage.Following the step, we found CD44 and phosphorylated tau expression upregulated in diabetic mice. We also found the insulin receptor substrate-1 (IRS1)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway dysregulated in diabetic mice. All these changes could be reversed by ECH. Our study provides theoretical support and experimental evidence for the future application of ECH in diabetic cognition dysfunction treatment, promoting the development of traditional medicines.","PeriodicalId":94001,"journal":{"name":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","volume":"221 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140746716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0